Novel imiquimod nanovesicles for topical vaccination

Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome?

“…Furthermore, oral administration of the immunosuppressant rapamycin has been shown to increase the immune response to influenza virus vaccination (higher antibody response) in older adults relative to those not having received rapamycin [55]. In addition to rapamycin, other small molecules and biologics with immunomodulatory function, such as imiquimod, are currently approved for clinical use [56][57][58]. Thus, the tools to modulate immune baseline status to potentially improve the outcome of vaccination are already available.…”

Superoxide dismutase in nanoarchaeosomes for targeted delivery to inflammatory macrophages

“…Specifically, ARC made of archaeolipids from Halorubrum tebenquichense contain PGP-Me, a ligand for scavenger receptors class A (SRA1) [25] highly expressed on macrophages and dendritic cells. Such naturally targeted ARC thus, facilitate the endocytic uptake of carried payload by macrophages with no aid of complex chemical derivatization [26,27].…”

Archaeosomes and Gas Vesicles as Tools for Vaccine Development

“…Topical application of ovalbumin (OVA) included in archaeosomes resulted in strong antibody responses to OVA in mice with a Th2 bias (19). Similar results were obtained when influenza vaccine was used as antigen and administered topically in an archaeosome formulation, which also resulted in a strong IFN-g response (20). A comparison of archaeosomes composed of TPLs from three different archaea applied topically revealed differences in their ability of antigen distribution and vesicle accumulation in the skin epidermis (21).…”